tiprankstipranks
Gentian Diagnostics Secures Patent for Diagnostic Precision
Company Announcements

Gentian Diagnostics Secures Patent for Diagnostic Precision

Gentian Diagnostics ASA (DE:6FK) has released an update.

Pick the best stocks and maximize your portfolio:

Gentian Diagnostics ASA has been granted a European patent for a novel reference method to improve accuracy in diagnostic assays, specifically for NT-proBNP concentration in blood samples. This mass spectrometry-based method will help harmonize NT-proBNP measurements, offering potential benefits to healthcare providers and patients. The company specializes in immunoassays and provides diagnostic reagents globally from its headquarters in Norway.

For further insights into DE:6FK stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskGentian Diagnostics Reports Strong Revenue Growth and Strategic Advances
TipRanks European Auto-Generated NewsdeskGentian Diagnostics Mourns Founder’s Passing
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App